Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02477696
Recruitment Status : Active, not recruiting
First Posted : June 23, 2015
Last Update Posted : April 17, 2019
Sponsor:
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : December 2020